Background-The efficacy and safety of drug-eluting stents (DES) in patients with ST-segment-elevation myocardial infarction (STEMI) is controversial. Consequently, DES implantation has a class IIa indication in the American College of Cardiology/American Heart Association and the European Society of Cardiology STEMI guidelines. Methods and Results-PUBMED, EMBASE, and CENTRAL were searched for randomized clinical trials, until March 2013, comparing any of the 5 Food and Drug Administration-approved durable stent and polymer DES (sirolimus eluting stent, paclitaxel eluting stent, everolimus-eluting stent [EES], zotarolimus-eluting stent, and zotarolimus-eluting stent resolute), against each other or bare metal stents (BMS), and enrolling ≥50 patients with STEMI. Efficacy (target vessel revascularization) and safety (death, myocardial infarction, and stent thrombosis) outcomes at the longest reported followup times were evaluated. Twenty-eight randomized clinical trials with 34 068 patient-years of follow-up on subjects with STEMI fulfilled the inclusion criteria. When compared with BMS (reference rate ratio [RR] of 1), sirolimus eluting stent (RR, 0.46; 95% credibility interval [CrI], 0.36-0.56), paclitaxel eluting stent (RR, 0.69; 95% CrI, 0.53-0.87), and EES (RR, 0.42; 95% CrI, 0
T he efficacy and safety of drug-eluting stents (DES) versus bare metal stents (BMS) in patients with ST-segmentelevation myocardial infarction (STEMI) is controversial with earlier registry studies and clinical trials showing no difference in death, recurrent myocardial infarction (MI), and even restenosis with DES, 1,2 but DES was associated with numerically excess stent thrombosis. 2, 3 Consequently, the American College of Cardiology (ACC)/American Heart Association (AHA) 4 and the European Society of Cardiology (ESC) guidelines 5 for the management of patients with STEMI give a class IIa recommendation for the use of a DES as an alternative to a BMS for primary percutaneous coronary intervention (PCI) in STEMI.
STEMI is a heightened state of thrombogenicity and the large amount of intracoronary thrombus during stent implantation may predispose to stent malapposition because of stent undersizing and later thrombus resolution, potentially increasing the likelihood of either stent thrombosis or restenosis. 6 In addition, delayed arterial healing with stent implantation in the acute MI setting has been shown to predispose to late stent thrombosis. 7 A more recent trial with a second-generation DES (everolimus-eluting stent [EES]) has shown a significant reduction of restenosis without any increase in death or MI when compared with BMS in patients with STEMI. 8, 9 Thus, there are emerging data to suggest that second-generation DES are not only as safe as BMS (perhaps safer), but also more efficacious. However, it is not known if this benefit is restricted to second-generation DES or to any 1 particular DES type and whether there are differences in efficacy and safety of the currently Food and Drug Administration (FDA)approved stents. We have recently shown in an analysis of 76 randomized clinical trials (RCTs) with 117 762 patient-years of follow-up, in patients undergoing PCI, that when compared with BMS, each DES reduced restenosis but the magnitude varied by DES type, with EES being the most efficacious and safest stent. 10 It is not known if this is applicable to patients with STEMI. Our objective was to evaluate the relative efficacy and safety of currently FDA-approved DES and BMS in patients with STEMI.
Methods

Eligibility Criteria
We conducted a systematic search for RCTs using the following databases: PUBMED, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), Google Scholar and using the search terms "drug eluting stent," "bare metal stent," and the names of individual FDA-approved durable polymer/stent DES systems (sirolimus eluting stent [SES] , paclitaxel eluting stent [PES], EES, Zotarolimus eluting stent [ZES] , and ZES-Resolute [ZES-R] stent), until March 2013 (week 1). The MeSH terms are listed in Appendix Table A in the online-only Data Supplement. We checked the reference lists of original studies, review articles, and meta-analyses identified by the electronic searches to find other eligible trials. There was no language restriction for the search. In addition, we searched conference proceedings/abstracts of the following societies: AHA, ACC, Society of Cardiovascular Angiography and Intervention, Transcatheter Cardiovascular Therapeutics, ESC, and Euro-PCR. For studies that did not report outcomes of interest, we contacted the authors via email. In addition, we reviewed the FDA dockets for all documents submitted during the stent approval process. The review was kept updated using automated weekly email alerts.
Eligible trials had to fulfill each of the following criteria: (1) RCTs comparing the above DES either with a different DES or with BMS in patients undergoing PCI; (2) trials enrolling subjects with STEMI or reporting data on the STEMI subgroup; (3) trials enrolling ≥50 patients with STEMI with follow-up of ≥6 months; and (4) trials reporting the outcomes of interest (below). Trials that used bioabsorbable scaffolds or polymer, nonpolymer stents, DES with the eluting drug other than the 5 compared (above), comparison of BMS with non-DES comparator, balloon angioplasty alone, or with coronary artery bypass graft surgery were excluded.
Selection and Quality Assessment
Four authors (S.B., S.K., M.F., and N.A.) independently assessed trial eligibility and trial bias risk and extracted data. Disagreements were resolved by consensus. The bias risk of trials was assessed using the components recommended by the Cochrane Collaboration 11 : sequence generation of the allocation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias. Trials with high or unclear risk for bias for any 1 of the first 3 components were considered as trials with high risk of bias. Otherwise, they were considered as trials with low risk of bias.
Data Extraction and Synthesis
We evaluated the following efficacy and safety outcomes. Efficacy outcome was target vessel revascularization (TVR). Safety outcomes evaluated included death, MI, and stent thrombosis. Outcomes were evaluated at the longest available follow-up time point. Four types of stent thrombosis were evaluated: any stent thrombosis (based on trial definition of stent thrombosis), Academic Research Consortium (ARC) 12 defined definite or probable stent thrombosis; ARC defined definite stent thrombosis and very late stent thrombosis (stent thrombosis >1 year). The search process was fairly extensive and efforts were made to obtain the longest reported follow-up data from a combination of sources: all the published trial data, data published in prior meta-analyses, presentations at national meetings, and unpublished data from author communication. Of note, the data for the ZES-R stent were based on only 1 trial and were available for the outcome of TVR and MI only.
Statistical Analyses
Mixed Treatment Comparisons
For the purpose of this analysis, 6 stent types were defined: BMS, SES, PES, EES, ZES, and ZES-R. Of note, the data for ZES-R were available for limited outcomes only (TVR and MI) and hence the pairwise analysis was done for 5 stent groups (without ZES-R) for outcomes where there were no data for ZES-R (such as death and stent thrombosis). The primary analysis compared each individual DES with BMS, which was used as reference. Bayesian models for mixed treatment comparison were used to compare the different stent types using WinBUGS 1.4.3 (MRC Biostatistics Unit, Cambridge, United Kingdom). 13 The mixed treatment comparison or network analysis allows for comparisons of devices not directly addressed within any of the individual trials by incorporating the indirect comparisons constructed from 2 trials that have 1 stent type in common (such as comparison of stent A versus C using trials comparing A versus B and B versus C). A burn-in phase of 50 000 simulations was
WHAT IS KNOWN
• The efficacy and safety of drug-eluting stents in a highly thrombotic milieu, such as those with STsegment-elevation myocardial infarction is not known, with reports of increase in late stent thrombosis with first-generation drug-eluting stents and is, therefore, a class IIa indication by American College of Cardiology/American Heart Association and European Society of Cardiology ST-segmentelevation myocardial infarction guidelines.
WHAT THE STUDY ADDS
• In patients with ST-segment-elevation myocardial infarction, drug-eluting stent versus bare metal stent was associated with substantial decrease in the risk of target vessel revascularization without compromising safety.
• In addition, everolimus-eluting stent had the added advantage of substantial reduction in the risk of stent thrombosis when compared with first-generation drug-eluting stents and bare metal stents with no increase in very late stent thrombosis. used to assess for convergence and a further 100 000 simulations were used for the final analyses.
Given the variability in the length of follow-up for each of these trials, we used the rate of outcomes per 1000 person-years to obtain the log rate ratios of 1 stent relative to another. Rates, rather than number of events, were considered the most appropriate outcome for these analyses because they incorporate the duration of the trials. Analysis was performed after taking into account the correlation structure induced by the multi-arm trials using a random-effect Poisson regression model. 14 A random-effect rather than a fixed-effect model was used as this is likely the most appropriate and conservative analysis to account for both within-study and between-study variance. In addition, a fixed-effect model was also constructed in a sensitivity analysis. Rate ratios were estimated from the median, and the accompanying 95% credibility intervals from the 2.5th and 97.5th percentiles of the posterior distribution. We then calculated the probability that a given stent is associated with the lowest event proportion for a particular outcome using a Bayesian Markov Chain Monte Carlo method, adapted to apply to a connected network set of treatment comparisons. Minimally informative prior distributions were used for log rate ratios and for random effects SDs, so the findings are close to those obtained with frequentist methods.
Heterogeneity and Goodness of Fit
Heterogeneity (τ 2 ) between trials, defined as variability of results across trials within comparisons over and above chance was evaluated on the basis of the methodology described previously, 15 with τ 2 estimate of 0.04 interpreted as a low, 0.14 as a moderate, and 0.40 as a high degree of heterogeneity between trials. In addition, the goodness of fit of the model to the data was estimated. 15 The model was considered to provide an adequate fit to the data if (1) the mean of the residual deviance was similar to the number of data points used in the model; (2) ≥95% of means of standardized node-based residuals were within ±1.96 of the standard normal distribution; and (3) Q-Q plots of residuals lied closely around a line on visual inspection. In addition, we evaluated the inconsistency of the network, defined as the variability of results across different comparisons of the network, by comparing the estimates from the network analysis with the rate ratio obtained from the direct comparison meta-analysis as described below.
Direct Comparison Meta-Analysis
Direct comparison meta-analysis was performed in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement, 11, 16 using standard software (Stata 9.0, Stata Corporation, TX). 17 Heterogeneity was assessed using the I 2 statistic, 18 which is the proportion of total variation observed between the trials attributable to differences between trials rather than sampling error (chance) with I 2 <25% considered low and I 2 >75% high. Rate ratio was calculated using the random-effect model of DerSimonian and Laird. 19 Bias was estimated visually by funnel plots and using the Begg's and the weighted regression test of Egger. 20 P<0.05 was used to denote statistical significance.
Sensitivity Analyses
Several sensitivity analyses were performed to assess fotr the robustness and consistency of the primary analysis. Analyses were restricted to (1) trials with low-bias risk; (2) trials where no routine angiographic follow-up was performed, as routine angiographic follow-up has been shown to increase the rate of repeat revascularization (occulostenotic reflex); and (3) trials where the duration of clopidogrel in the DES arm was ≥6 months (to avoid confounding effect of shorter duration clopidogrel treatment on safety outcomes).
Results
Study Selection and Characteristics of Included Trials
We identified 28 RCTs with 14 740 patients with STEMI and with 34 068 patient-years of follow-up that satisfied our inclusion criteria (Appendix Figure AI in the onlineonly Data Supplement). The network of stent comparisons is shown in Figure 1 . There were five 3-arm trials with the remainder being 2-arm trials ( Table 1) . Of note, all EES used in the included RCTs was the cobalt chromium EES and not the platinum chromium EES. Twenty trials were trials with low risk of bias, whereas 8 trials were trials with unclear or high risk of bias ( Table 2 ). The majority of trials (26 trials) used clopidogrel for ≥6 months in the DES arm and 15 trials had no routine angiographic follow-up (Tables 1 and 2 ). The mean follow-up was 2.2 years (range, 6 months to 5 years).
Efficacy Outcome (TVR)
When compared with BMS (reference rate ratio [RR] of 1), SES (number needed to treat [NNT]=29 [95% confidence interval, [27] [28] [29] [30] , PES (NNT=51 ) and EES (NNT=27 [25-31]) were associated with a statistically significant reduction in rate of TVR, with the point estimate for ZES-R being in a similar position ( Figure 2A ; Table 3 ). SES was significantly more efficacious than BMS (54% reduction) and PES (49% reduction); PES was significantly more efficacious than BMS (31% reduction); EES was significantly more efficacious than BMS (58% reduction) and PES (40% reduction); with no difference in the other pairwise comparisons between the stents (Figure 2 ). There was a 67% and 21% probability that ZES-R and EES, respectively, have the lowest TVR rate when compared with all other stent types (Appendix Figure  AII in the online-only Data Supplement). The data on ZES-R were based on 1 trial with 281 patients and had wide credibility intervals. When the analysis was repeated excluding ZES-R, there was a 58% probability that EES had the lowest TVR rate compared with all other stent types.
The results were largely similar in the various sensitivity analyses: in trials with low-bias risk (Appendix Table B in the online-only Data Supplement); analyses after excluding trials with routine angiographic follow-up (Appendix Table C in the online-only Data Supplement) and analysis including only trials with ≥6 months of clopidogrel use (Appendix Figure AIII in the online-only Data Supplement); and in the direct comparison meta-analysis (Appendix Tables D and E in the online-only Data Supplement). The between-trial heterogeneity for the various network models showed low heterogeneity for the analyses (Appendix Table F 
Safety Outcomes
Death
There was no available data on death for the ZES-R. When compared with BMS (reference RR of 1), none of the compared DES were associated with a statistically significant increased rate of death ( Figure 3A ; Table 3 ). Similarly, there was no statistically significant difference between the other pairwise comparisons of stents ( Figure 3A ). There was a 64% probability that EES has the lowest death rate when compared with all other stent types (Appendix Figure AIV in the onlineonly Data Supplement).
The results were largely similar in the various sensitivity analyses: in trials with low-bias risk (Appendix Table B in the online-only Data Supplement); analyses after excluding trials with routine angiographic follow-up (Appendix Table C in the online-only Data Supplement) and analysis including only trials with ≥6 months of clopidogrel use (Appendix Figure AV in the online-only Data Supplement); and in the direct comparison meta-analysis (Appendix Tables D and E in the online-only Data Supplement). The between-trial heterogeneity for the various network models showed low heterogeneity for the analyses (Appendix Table F 
Myocardial Infarction
When compared with BMS (reference RR of 1), none of the compared DES were associated with a statistically significant increased rate of MI ( Figure 3B ; Table 3 ). Similarly, there was no statistically significant difference between any pairwise comparisons of stents ( Figure 3B ). There was a 48% and 44% Figure 2 . Stent type and risk of target vessel revascularization (TVR). The numbers represents rate ratio (RR) and 95% credibility intervals (CrI). BMS indicates bare metal stent. The results were largely similar in the various sensitivity analyses: in trials with low-bias risk (Appendix Table B in the online-only Data Supplement); analyses after excluding trials with routine angiographic follow-up (Appendix Table C in the online-only Data Supplement) and analysis including only trials with ≥6 months of clopidogrel use (Appendix Figure AVII in the online-only Data Supplement); and in the direct comparison meta-analysis (Appendix Tables D and E in the onlineonly Data Supplement). The between-trial heterogeneity for the various network models showed low-to-moderate heterogeneity for the analyses (Appendix Table F 
Table 3. Median Rate (per 1000 Patient-Years of Follow-up) of Selected Efficacy and Safety Outcomes and the Probability That Each Stent Type Is the Best (Lowest Rate) From Mixed Treatment Comparison Analysis
Stent Thrombosis
There was no available data on stent thrombosis for the ZES-R. When compared with BMS (reference RR of 1), EES was associated with a statistically significant reduction (58%) in the rate of any stent thrombosis (NNT=92 [98-109]; Figure 4A ; Table 3 ). Similarly, EES was associated with a statistically significant lower rate of any stent thrombosis when compared with SES (62% reduction) and PES (61% reduction) with no statistically significant difference between any other pairwise comparisons of stents ( Figure 4A ). There was a 74% probability that EES had the lowest rate of any stent thrombosis compared with all other stent types (Appendix Figure AVIII analyses in trials with low-bias risk (Appendix Table B in the online-only Data Supplement); analyses after excluding trials with routine angiographic follow-up (Appendix Table C in the online-only Data Supplement) and analysis including only trials with ≥6 months of clopidogrel use (Appendix Figures AIX, AXI, and AXIII in the online-only Data Supplement); and in the direct comparison meta-analysis (Appendix Tables D and E in the online-only Data Supplement). The between-trial heterogeneity for the various network models showed low heterogeneity for the analyses (Appendix Table F 
Very Late Stent Thrombosis
There was no available data on very late stent thrombosis for the ZES-R. When compared with BMS (reference RR of 1), none of the DES were associated with a statistically significant increase in very late stent thrombosis (Appendix Figure AXIV in the online-only Data Supplement). However, the point estimate for SES and PES indicated a numerically higher rate of very late stent thrombosis when compared with BMS. There was however, no increase in the risk of very late stent thrombosis with EES compared with BMS. There was a 53% and 42% probability, respectively, that EES and BMS had the lowest very late stent thrombosis rate when compared with all other stent types (Appendix Figure AXV in the online-only Data Supplement).
Discussion
This study, the largest thus far, evaluated the long-term comparison of efficacy and safety among currently FDA-approved DES and BMS in patients with STEMI. The principal results, with data from 28 RCTs and 34 068 patient-years of followup, showed that DES reduced the risk of TVR without increasing the rate of any adverse safety outcomes, including stent thrombosis when compared with BMS. Among DES, EES was associated with the lowest TVR rate (NNT=27) and had the best safety profile with reduction in the risk of stent thrombosis (NNT=92) when compared with first-generation DES and even BMS and with no increase in very late stent thrombosis. More data are needed for the ZES-R.
DES in STEMI
STEMI is a heightened state of thrombosis and concerns have been raised about the risk of stent thrombosis when a stent is implanted in such a thrombotic milieu. Moreover, there is a risk of underdeployment of stent because of the underlying thrombus, and the risk of late stent malapposition when the thrombus resolves which can predispose to both restenosis and stent thrombosis. 6 In addition, delayed arterial healing with stent implantation in the acute MI setting has been shown to also contribute to late stent thrombosis. 7 With the advances in antiplatelet and antithrombotic therapy, PCI using BMS has been proven to be safe, with reduction in restenosis when compared with balloon angioplasty alone with no increase in death or recurrent MI. Although DES have made substantial inroads at reducing the risk of restenosis when compared with BMS, BMS have been considered the benchmark for safety, and this is especially true for patients with STEMI. Initial registry studies and clinical trials not only showed no benefit of DES at preventing restenosis in patients with STEMI, 1,2 but also a numeric excess of stent thrombosis when compared with BMS. 2 In addition, it is difficult to predict patient compliance to antiplatelet therapy, an extremely important predictor of stent thrombosis, before PCI in the setting of STEMI. Consequently, the ACC/AHA and the ESC guidelines for the management of patients with STEMI list a class IIa recommendation for the use of DES as an alternative to BMS for primary PCI in STEMI. 4, 5 Therefore, worldwide a substantial number of patients with STEMI continue to receive BMS.
Subsequent to these data, several recent trials and analyses have shown that first-generation DES are effective at preventing the risk of restenosis when compared with BMS. However, the question on stent thrombosis and especially very late stent thrombosis (>1 year) has persisted. In a large-scale individual patient data meta-analysis of 11 trials with 6298 patients with STEMI, DES implantation was associated with a significant reduction in the risk of (TVR; hazard ratio, 0.57; 95% confidence interval, 0.50-0.66) without any significant difference in mortality, reinfarction, and stent thrombosis. 24 However, first-generation DES implantation was associated with an increased risk of very late stent thrombosis and reinfarction. 24 In our study, we noted a similar numerically higher rate of very late stent thrombosis with SES and PES, although these were not statistically significant, while there was no increase in the risk of very late stent thrombosis with EES when compared with BMS. Our study differs from the analysis of De Luca et al 24 The second-generation DES have thinner struts and novel biocompatible polymer, both of which are designed to reduce inflammation, which can result in both restenosis and stent thrombosis. The second-generation DES, especially EES, have been shown to be efficacious at reducing the risk of restenosis in a variety of setting in patients without acute coronary syndromes and even in those with diabetes mellitus. 10, 58 Data for ZES-R suggest a similar efficacy profile as that of EES. 10, 59, 60 Moreover, EES was found to be safe with no increased risk of death and with reduction in the risk of MI and stent thrombosis, when compared with BMS. 10 However, it was not known whether the above benefit applied to patients with STEMI. The results of the present analysis in patients with STEMI are consistent with the prior large-scale analysis showing a substantial benefit of DES (SES, PES, and EES) at reducing the risk of TVR when compared with BMS in patients with STEMI. The result for ZES-R was based on a small subgroup of 281 patients with STEMI from the Resolute All Comers trial and the point estimate was similar as above for TVR, although this was not statistically significant. In fact, in the probability analysis, both ZES-R and EES had the lowest TVR rate, consistent with previous analysis. 10 This effect was consistent even when excluding trials with routine protocol-directed angiographic follow-up, which is important in excluding TVR resulting from the oculostenotic reflex.
Our results also show that DES are safe with no increase in the risk of death, MI, or stent thrombosis when compared with BMS. In addition, EES was associated with a substantial decrease in the risk of stent thrombosis when compared with first-generation DES (SES and PES) and also when compared with BMS. This is similar to the results seen in prior studies extending to non-acute coronary syndrome cohorts. 10 The results were consistent in several sensitivity analysis, including restriction to trials with clopidogrel duration of ≥6 months. The decreased risk of stent thrombosis with EES when compared with BMS has also been seen in a recent randomized trial. In the clinical Evaluation of Xience-V stent in Acute Myocardial Infarction (EXAMINATION) trial, patients with STEMI randomized to EES had lower 1-year TVR (3.9% versus 7.0%; P=0.007) with no difference for death or MI when compared with BMS. 8 In addition, EES was associated with a significant reduction in definite stent thrombosis (0.5% versus 1.9%; P=0.01) and definite/probable stent thrombosis (0.9% versus 2.6%; P=0.01) when compared with BMS. 8 In a recent study and contrary to popular belief, thrombogenicity of polymercoated stents with thin struts (such as EES) was lowest and this remained insensitive even to incomplete deployment of the stent even when compared with BMS, 61 attesting to the possible cause for a lower stent thrombosis with EES even when compared with BMS.
The results of the present study have important implications: given the superior efficacy and even safety of DES, especially EES and perhaps ZES-R, these stents should be considered a class I indication for patients with STEMI. In fact, the ACC/ AHA/Society of Cardiac Angiography and Intervention 2011 PCI guidelines state that once a decision for PCI has been made, there is a class I recommendation for DES rather than BMS in patients with unstable angina, STEMI, and non-STEMI at high risk for restenosis. 62 In addition, the totality of data with results from cohorts, including non-acute coronary syndrome patients, patients with diabetes mellitus, and now patients with STEMI, suggest that DES (especially EES) should be the benchmark for both efficacy and safety for future clinical trials. However despite the above, in patients undergoing emergent PCI, such as those with STEMI, it may not be possible to accurately assess the compliance with antiplatelet agents. In addition, there was no benefit of reduction of death or MI with DES versus BMS and the absolute risk reduction for TVR is likely less than that in patients without STEMI with the added cost of prolonged dual antiplatelet therapy and the increased risk of bleeding. Nevertheless, these data should be taken into consideration in the decision making for patients with STEMI.
Limitations
As in other meta-analyses, despite detailed sensitivity analyses on many variables, confounding by indication cannot be ruled out. The study evaluated trial-level data only and hence cannot account for between-group differences in cotherapies. Not all of the trials reported each of the outcomes assessed. The results of the sensitivity analyses are best described as secondary and hypothesis generating only. The differences seen within DES types are only applicable to the specific stents evaluated in this study. Nonetheless, this study, which is the largest meta-analysis to date, offers important insights into their relative safety and efficacy among currently FDAapproved DES and BMS in patients with STEMI.
Conclusions
In this analysis of the largest series to date, with data from 28 RCTs with 34 068 patient-years of follow-up of patients with STEMI, DES (especially EES and probably ZES-R) were associated with significant reduction in the risk of restenosis. Furthermore, EES was associated with a substantial reduction in the risk of stent thrombosis when compared with first-generation DES and even BMS without any increase in the risk of very late stent thrombosis. More data are need for ZES-R. Treatment of 1000 patients with STEMI with EES results in 37 fewer TVR and 11 fewer stent thrombosis when compared with PCI using BMS.
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